Gennex Laboratories Intrinsic Value
GENNEX Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹18.48 | ₹14.78 - ₹22.18 | +36.1% | EPS: ₹0.84, Sector P/E: 22x |
| Book Value Method | asset | ₹33.95 | ₹30.56 - ₹37.35 | +150.0% | Book Value/Share: ₹84.78, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹27.16 | ₹24.44 - ₹29.88 | +100.0% | Revenue/Share: ₹67.83, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹27.16 | ₹24.44 - ₹29.88 | +100.0% | EBITDA: ₹32.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹33.95 | ₹27.16 - ₹40.74 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹5.38 | ₹4.84 - ₹5.92 | -60.4% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹12.98 | ₹11.68 - ₹14.28 | -4.4% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹27.16 | ₹24.44 - ₹29.88 | +100.0% | ROE: 12.3%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹40.03 | ₹36.03 - ₹44.03 | +194.8% | EPS: ₹0.84, BVPS: ₹84.78 |
Want to compare with current market value? Check GENNEX share price latest .
Valuation Comparison Chart
GENNEX Intrinsic Value Analysis
What is the intrinsic value of GENNEX?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Gennex Laboratories (GENNEX) is ₹27.16 (median value). With the current market price of ₹13.58, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹5.38 to ₹40.03, indicating ₹5.38 - ₹40.03.
Is GENNEX undervalued or overvalued?
Based on our multi-method analysis, Gennex Laboratories (GENNEX) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 10.65 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.31 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 12.3% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 15.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.61x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Gennex Laboratories
Additional stock information and data for GENNEX
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-11 Cr | ₹-11 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-47 Cr | ₹-47 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹24 Cr | ₹5 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹12 Cr | ₹11 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹-1 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |